Searchable abstracts of presentations at key conferences in endocrinology

ea0063p1020 | Interdisciplinary Endocrinology 2 | ECE2019

Circulating miRNAs expression profile in in vitro muscle cell model exposed to cortisol excess

Patalano Roberta , Pivonello Claudia , Monto Tatiana , Simeoli Chiara , Negri Mariarosaria , Di Gennaro Gilda , Papa Fortuna , de Angelis Cristina , Cristina De Martino Maria , Pivonello Rosario

CushingÂ’s Syndrome (CS) is associated with a severe myopathy mainly affecting type 2 muscle fibres, with a higher prevalence in male subjects. The excess of glucocorticoids (GC) levels represents the most common cause of myopathy due to an alteration of protein metabolism. The non-coding post-transcriptional gene regulators muscle-specific microRNAs (miRNA) control muscle development and differentiation but when dysregulated lead to skeletal muscle (SM) disorder. The aim ...

ea0070aep530 | Endocrine-related Cancer | ECE2020

Reversal effect of Vitamin D (VitD) on exosome-mediated everolimus resistance (EveR) in hepatocellular carcinoma (HCC) cell line: A molecular study

Gentile Annalisa , Negri Mariarosaria , Montò Tatiana , Patalano Roberta , de Angelis Cristina , Simeoli Chiara , Ferrigno Rosario , Cristina De Martino Maria , Simona Auriemma Renata , Colao Annamaria , Pivonello Rosario , Pivonello Claudia

Cancer exosomes emerged as important mediators of cancer drug resistance. Drug exposure-mediated EveR in HCC cell lines can be reversed by VitD pre- and co-treatment. The current study aimed to investigate whether cancer exosomes from EveR HCC cell line are able to induce EveR in parental cells and whether VitD may activate reversal effect on exosome-mediated EveR.To this purpose, parental JHH-6 and EveR JHH-6 cell line were used. The uptakeof exosomes, ...

ea0056p674 | Nuclear receptors and Signal transduction | ECE2018

1,25 dihydroxyvitamin D reverses everolimus resistance in hepatocellular carcinoma activating mesenchymal-epithelial transition and miR-375

Pivonello Claudia , Paola Provvisiero Donatella , Negri Mariarosaria , Di Gennaro Gilda , de Angelis Cristina , Patalano Roberta , Galdiero Giacomo , Simeoli Chiara , Simona Auriemma Renata , Cristina De Martino Maria , Colao Annamaria , Pivonello Rosario

HCC is a difficult-to-treat-cancer with poor prognosis. EVOLVE-1 trial demonstrated that EVE did not improve overall survival in molecularly and clinically unselected patients with advanced HCC resistant to sorafenib. In selected patients, the well-established antitumor effect of EVE could make this a potential adjuvant therapy. Unfortunately, EVE acquired resistance due to the tumor adaptation to chronic drug use is a current challenge. VitD was deemed as potential regimen to...